Trigeminal Neuralgia Treatment Market Size, Share, Competitive Landscape and Trend Analysis Report by Treatment Type, Treatment Provider, and Region: Global Opportunity Analysis and Industry Forecast, 2024-2033

The trigeminal neuralgia treatment market was valued at $250.47 million in 2023 and is estimated to reach $397.27 million by 2033, exhibiting a CAGR of 5.1% from 2024 to 2033.

Market Definition and Overview

Trigeminal neuralgia is a chronic pain condition affecting the trigeminal nerve, causing intense, stabbing pain in the face. Treatment aims to relieve pain and improve quality of life. Medications like anticonvulsants (e.g., carbamazepine) are often prescribed to manage symptoms by reducing nerve impulses. Surgery may be considered for cases resistant to medication, such as microvascular decompression to relieve pressure on the nerve or stereotactic radiosurgery to damage the nerve and disrupt pain signals. Alternative therapies like acupuncture or nerve blocks can provide additional relief for some individuals. The condition’s name, ‘trigeminal,’ refers to the trigeminal nerve, which divides into three branches that transmit sensory information from the face to the brain. ‘Neuralgia’ signifies nerve pain, specifically characterized by sudden, severe bursts of pain along the affected nerve pathways. Early diagnosis and tailored treatment plans are essential to manage symptoms effectively and enhance daily functioning for those affected by trigeminal neuralgia.

Key Takeaways

• The trigeminal neuralgia treatment market study covers 20 countries. The research includes a segment analysis of each country in terms of value ($million) for the projected period from 2024 to 2033.
• More than 1,500 product literatures, industry releases, annual reports, and other such documents of major trigeminal neuralgia treatment industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
• The study integrates high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach intends to provide a balanced view of global markets and assist stakeholders in making informed decisions in order to achieve their most ambitious growth objectives.

Industry Trends

• In March 2023, Noema Pharma, a Swiss biotech company specializing in treating severe central nervous system disorders, successfully concluded a Series B funding round. The company raised CHF 103 million ($112 million) from both existing and new investors, exceeding initial expectations. The funds will primarily support the advancement of its clinical-stage assets, notably basimglurant (NOE-101). Basimglurant, an mGluR5 inhibitor, is currently in phase 2b trials for treating severe pain associated with trigeminal neuralgia (TN) and seizures in patients with tuberous sclerosis complex (TSC).
• In December 2021, the International Diabetes Federation, an intergovernmental organization based in the U.S., reported that diabetes impacted 537 million adults aged 20-79 years. They projected that this number would rise to 643 million by 2030 and to 783 million by 2045. Consequently, the increasing incidence of chronic conditions like diabetes is driving the expansion of the neuralgia treatment industry.

Key Market Dynamics

Technological advancements in imaging, such as MRI and CT scans, enable better diagnosis and monitoring of trigeminal neuralgia, leading to more targeted treatments. Developments in medical treatments, including surgical procedures like microvascular decompression (MVD), gamma knife radiosurgery, and radiofrequency ablation, provide more choices for patients and contribute to market growth. Rising awareness among patients and healthcare providers about trigeminal neuralgia and its management options is driving early diagnosis and treatment initiation.

Surgical treatments for trigeminal neuralgia, such as MVD and radiosurgery, carry risks of complications such as facial numbness, hearing loss, and in rare cases, stroke. These potential side effects may deter some patients from opting for these treatments. Many of the advanced treatments for trigeminal neuralgia, such as microvascular decompression (MVD) and gamma knife radiosurgery, can be costly. This cost may limit access for patients without adequate insurance coverage or in regions with limited healthcare resources.

Awareness regarding trigeminal neuralgia (TN) is increasing among healthcare professionals and public, resulting in earlier diagnoses through educational initiatives, medical conferences, and awareness campaigns. This increased recognition has led to greater demand for effective treatments. Research organizations such as the Trigeminal Neuralgia Association, the National Organization for Rare Disorders (NORD), the American Chronic Pain Association, the Facial Pain Association (FPA), the Brain & Life Organization, and the National Institute of Neurological Disorders and Stroke are actively investigating the underlying mechanisms of chronic pain and trigeminal neuralgia.

Patent Analysis of Global Trigeminal Neuralgia Treatment Market

A patent application titled ‘FUROINDAZOLE DERIVATIVES FOR THE TREATMENT OF PAIN,’ filed by BAYER AKTIENGESELLSCHAFT [DE], was published on April 25, 2024. The invention pertains to the use of furoindazole compounds described by general formula (I), where R1, R2, R3, R4, R5, R6, R7a, and R7b are specified, for treating or preventing various diseases. These include inflammatory-driven pain diseases such as diabetic neuropathic pain, chemotherapy-induced pain, post-breast surgery pain, cancer bone pain, trigeminal neuralgia, post-mastectomy pain, fibromyalgia, multiple sclerosis pain, post-herpetic neuralgia, Fabry disease, gout, and bladder pain syndrome in both humans and animals.

Market Segmentation

The trigeminal neuralgia treatment market is segmented into treatment type, treatment provider, and region. On the basis of treatment type, the market is divided into drugs and surgeries. On the basis of treatment provider, the market is classified into hospitals & clinics, ambulatory surgery centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Regional Market Outlook

Rising healthcare spending in countries like China, India, Japan, and South Korea is improving access to advanced medical treatments, including those for neurological conditions like trigeminal neuralgia. Due to the rising aging population across Asia-Pacific countries, there is a higher prevalence of neurological disorders such as trigeminal neuralgia, driving demand for effective treatments. Improvements in diagnostic tools and surgical techniques, including microvascular decompression (MVD) and gamma knife radiosurgery, are enhancing treatment outcomes and expanding the regional market.

• In March 2023, a study published in the Japanese Journal of Neurosurgery highlighted the efficacy of gamma knife radiosurgery in treating trigeminal neuralgia patients, emphasizing its role as a non-invasive alternative to traditional surgical methods.
• In January 2023, The Times of India reported on advancements in microvascular decompression surgery for trigeminal neuralgia at a leading hospital in Mumbai, showcasing the procedure's success in alleviating pain and improving quality of life for patients.

Competitive Landscape

The major players operating in the trigeminal neuralgia treatment market include Biogen, Inc., Trigemina Inc., Allergan Plc, Lupin, Merz Pharma GmbH, GlaxoSmithKline Plc., Novartis, Abbott Laboratories, PixarBio Corporation, Pfizer Inc., and others.

Recent Key Strategies and Developments

• In November 2021, AbbVie, the parent company of Allergan, disclosed promising outcomes from a Phase 3 clinical trial assessing Ubrogepant for episodic migraine treatment, an area where treatment strategies may overlap with those for trigeminal neuralgia.
• In February 2019, Zydus Cadila received FDA approval to market Carbamazepine, a medication prescribed for the treatment of neuralgia.

Key Sources Referred

1. Company Annual Reports
2. Investor Presentations
3. Press Release
4. Research Paper
5. D&B Hoovers
6. ZoomInfo Technologies LLC
7. National Institutes of Health (NIH) (.gov)
8. European Journal of Medical and Health Sciences
9. Neurosciences Journal

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the trigeminal neuralgia treatment market segments, current trends, estimations, and dynamics of the trigeminal neuralgia treatment market analysis from 2023 to 2033 to identify the trigeminal neuralgia treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the trigeminal neuralgia treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global trigeminal neuralgia treatment market statistics.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

Apart from the points mentioned above, the report includes the analysis of the regional as well as global trigeminal neuralgia treatment market trends, key players, market segments, application areas, and market growth strategies.

1. Research Methodology

1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.5. Market size estimation

1.5.1. Top-down approach
1.5.2. Bottom-up approach

2. Report Scope

2.1. Market definition
2.2. Key objectives of the study
2.3. Report overview
2.4. Market segmentation
2.5. Overview of the impact of COVID-19 on global Trigeminal Neuralgia Treatment Market    

3. Executive Summary
4. Market Overview

4.1. Introduction
4.2. Growth impact forces

4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities

4.3. Market value chain analysis

4.3.1. List of raw material suppliers
4.3.2. List of manufacturers 
4.3.3. List of distributors

4.4. Innovation & sustainability matrices

4.4.1. Technology matrix
4.4.2. Regulatory matrix

4.5. Porter’s five forces analysis

4.5.1. Bargaining power of suppliers
4.5.2. Bargaining power of consumers
4.5.3. Threat of substitutes
4.5.4. Threat of new entrants
4.5.5. Competitive rivalry intensity

4.6. PESTLE analysis

4.6.1. Political
4.6.2. Economical
4.6.3. Social
4.6.4. Technological
4.6.5. Legal
4.6.6. Environmental

4.7. Impact of COVID-19 on Trigeminal Neuralgia Treatment Market    

4.7.1. Pre-covid market scenario
4.7.2. Post-covid market scenario

5. Trigeminal Neuralgia Treatment Market Analysis, by Treatment Type

5.1. Overview
5.2. Drugs

5.2.1. Definition, key trends, growth factors, and opportunities
5.2.2. Market size analysis, by region, 2023-2033
5.2.3. Market share analysis, by country, 2023-2033

5.3. Surgeries

5.3.1. Definition, key trends, growth factors, and opportunities
5.3.2. Market size analysis, by region, 2023-2033
5.3.3. Market share analysis, by country, 2023-2033

5.4. Research Dive Exclusive Insights

5.4.1. Market attractiveness
5.4.2. Competition heatmap

6. Trigeminal Neuralgia Treatment Market Analysis, by Treatment Provider 

6.1. Overview
6.2. Hospitals & Clinics   

6.2.1. Definition, key trends, growth factors, and opportunities
6.2.2. Market size analysis, by region, 2023-2033
6.2.3. Market share analysis, by country, 2023-2033

6.3. Ambulatory Surgery Centers

6.3.1. Definition, key trends, growth factors, and opportunities
6.3.2. Market size analysis, by region, 2023-2033
6.3.3. Market share analysis, by country, 2023-2033

6.4. Others

6.4.1. Definition, key trends, growth factors, and opportunities
6.4.2. Market size analysis, by region, 2023-2033
6.4.3. Market share analysis, by country, 2023-2033

6.5. Research Dive Exclusive Insights

6.5.1. Market attractiveness
6.5.2. Competition heatmap

7. Trigeminal Neuralgia Treatment Market, by Region

7.1. North America

7.1.1. U.S.

7.1.1.1. Market size analysis, by Treatment Type, 2023-2033
7.1.1.2. Market size analysis, by Treatment Provider, 2023-2033

7.1.2. Canada

7.1.2.1. Market size analysis, by Treatment Type, 2023-2033
7.1.2.2. Market size analysis, by Treatment Provider, 2023-2033

7.1.3. Mexico

7.1.3.1. Market size analysis, by Treatment Type, 2023-2033
7.1.3.2. Market size analysis, by Treatment Provider, 2023-2033

7.1.4. Research Dive Exclusive Insights

7.1.4.1. Market attractiveness
7.1.4.2. Competition heatmap

7.2. Europe

7.2.1. Germany 

7.2.1.1. Market size analysis, by Treatment Type, 2023-2033
7.2.1.2. Market size analysis, by Treatment Provider, 2023-2033

7.2.2. UK

7.2.2.1. Market size analysis, by Treatment Type, 2023-2033
7.2.2.2. Market size analysis, by Treatment Provider, 2023-2033

7.2.3. France

7.2.3.1. Market size analysis, by Treatment Type, 2023-2033
7.2.3.2. Market size analysis, by Treatment Provider, 2023-2033

7.2.4. Spain

7.2.4.1. Market size analysis, by Treatment Type, 2023-2033
7.2.4.2. Market size analysis, by Treatment Provider, 2023-2033

7.2.5. Italy

7.2.5.1. Market size analysis, by Treatment Type, 2023-2033
7.2.5.2. Market size analysis, by Treatment Provider, 2023-2033

7.2.6. Rest of Europe

7.2.6.1. Market size analysis, by Treatment Type, 2023-2033
7.2.6.2. Market size analysis, by Treatment Provider, 2023-2033

7.2.7. Research Dive Exclusive Insights

7.2.7.1. Market attractiveness
7.2.7.2. Competition heatmap

7.3. Asia-Pacific

7.3.1. China

7.3.1.1. Market size analysis, by Treatment Type, 2023-2033
7.3.1.2. Market size analysis, by Treatment Provider, 2023-2033

7.3.2. Japan 

7.3.2.1. Market size analysis, by Treatment Type, 2023-2033
7.3.2.2. Market size analysis, by Treatment Provider, 2023-2033

7.3.3. India

7.3.3.1. Market size analysis, by Treatment Type, 2023-2033
7.3.3.2. Market size analysis, by Treatment Provider, 2023-2033

7.3.4. Australia

7.3.4.1. Market size analysis, by Treatment Type, 2023-2033
7.3.4.2. Market size analysis, by Treatment Provider, 2023-2033

7.3.5. South Korea

7.3.5.1. Market size analysis, by Treatment Type, 2023-2033
7.3.5.2. Market size analysis, by Treatment Provider, 2023-2033

7.3.6. Rest of Asia-Pacific

7.3.6.1. Market size analysis, by Treatment Type, 2023-2033
7.3.6.2. Market size analysis, by Treatment Provider, 2023-2033

7.3.7. Research Dive Exclusive Insights

7.3.7.1. Market attractiveness
7.3.7.2. Competition heatmap

7.4. LAMEA

7.4.1. Brazil

7.4.1.1. Market size analysis, by Treatment Type, 2023-2033
7.4.1.2. Market size analysis, by Treatment Provider, 2023-2033

7.4.2. Saudi Arabia

7.4.2.1. Market size analysis, by Treatment Type, 2023-2033
7.4.2.2. Market size analysis, by Treatment Provider, 2023-2033

7.4.3. UAE

7.4.3.1. Market size analysis, by Treatment Type, 2023-2033
7.4.3.2. Market size analysis, by Treatment Provider, 2023-2033

7.4.4. South Africa

7.4.4.1. Market size analysis, by Treatment Type, 2023-2033
7.4.4.2. Market size analysis, by Treatment Provider, 2023-2033

7.4.5. Rest of LAMEA

7.4.5.1. Market size analysis, by Treatment Type, 2023-2033
7.4.5.2. Market size analysis, by Treatment Provider, 2023-2033

7.4.6. Research Dive Exclusive Insights

7.4.6.1. Market attractiveness
7.4.6.2. Competition heatmap

8. Competitive Landscape

8.1. Top winning strategies, 2022

8.1.1. By strategy
8.1.2. By year

8.2. Strategic overview
8.3. Market share analysis, 2023

9. Company Profiles

9.1. Biogen, Inc.
9.1.1. Overview
9.1.2. Business segments
9.1.3. Product portfolio
9.1.4. Financial performance
9.1.5. Recent developments
9.1.6. SWOT analysis

9.2. Trigemina Inc.

9.2.1. Overview
9.2.2. Business segments
9.2.3. Product portfolio
9.2.4. Financial performance
9.2.5. Recent developments
9.2.6. SWOT analysis

9.3. Allergan Plc

9.3.1. Overview
9.3.2. Business segments
9.3.3. Product portfolio
9.3.4. Financial performance
9.3.5. Recent developments
9.3.6. SWOT analysis

9.4. Lupin

9.4.1. Overview
9.4.2. Business segments
9.4.3. Product portfolio
9.4.4. Financial performance
9.4.5. Recent developments
9.4.6. SWOT analysis

9.5. Merz Pharma GmbH

9.5.1. Overview
9.5.2. Business segments
9.5.3. Product portfolio
9.5.4. Financial performance
9.5.5. Recent developments
9.5.6. SWOT analysis

9.6. GlaxoSmithKline Plc.

9.6.1. Overview
9.6.2. Business segments
9.6.3. Product portfolio
9.6.4. Financial performance
9.6.5. Recent developments
9.6.6. SWOT analysis

9.7. Novartis

9.7.1. Overview
9.7.2. Business segments
9.7.3. Product portfolio
9.7.4. Financial performance
9.7.5. Recent developments
9.7.6. SWOT analysis

9.8. PixarBio Corporation.

9.8.1. Overview
9.8.2. Business segments
9.8.3. Product portfolio
9.8.4. Financial performance
9.8.5. Recent developments
9.8.6. SWOT analysis

9.9. Abbott Laboratories

9.9.1. Overview
9.9.2. Busiess segments
9.9.3. Product portfolio
9.9.4. Financial performance
9.9.5. Recent developments
9.9.6. SWOT analysis

9.10. Pfizer Inc.

9.10.1. Overview
9.10.2. Business segments
9.10.3. Product portfolio
9.10.4. Financial performance
9.10.5. Recent developments
9.10.6. SWOT analysis

* Taxes/Fees, If applicable will be added during checkout. All prices in USD.